0.00Open0.00Pre Close0 Volume0 Open Interest32.50Strike Price0.00Turnover0.00%IV-74.64%PremiumOct 4, 2024Expiry Date13.89Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.35Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
i will shot this till $15
Larger Image: tradingview.com...
$Summit Therapeutics (SMMT.US)$
10 clinical trials to watch in the second half of 2024 | BioPharma Dive
Analysts raised price targets for Summit, speculating that Ivonescimab could challenge Keytruda in the $50 billion lung cancer drug market. Summit also raised $235 mill...
not no no...
$Summit Therapeutics (SMMT.US)$
No comment yet